By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug Administration granted regular approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On the date of approval, the U.S. Food and Drug Administration approved Nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment. This
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with Fulvestrant for adult patients with hormone receptor
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration granted accelerated approval for Pirtobrutinib (Jaypirca) to be administered to adult patients diagnosed with chronic lymphocytic leukemia (CLL) or small
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 8, 2023, the U.S. Food and Drug Administration granted approval to Fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients who have metastatic colorectal cancer
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination with chemotherapy for adult patients with metastatic or locally advanced nasopharyngeal carcinoma
More
By: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (R/R MDS) with a susceptible isocitrate dehydrogenase-1
More
By Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration approved pembrolizumab for patients with resectable non-small cell lung cancer (NSCLC) tumors
More
On October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor) for patients with metastatic non-small cell lung cancer (NSCLC) that was detected
More
On September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1 year of age and older. Previously, bosutinib had been approved for adults
More
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) without prior erythropoiesis-stimulating agent (ESA) use,
More